Ipatasertib ‘Modestly’ Prolongs PFS in Triple-Negative Breast Cancer

Adding ipatasertib to first-line paclitaxel modestly improved progression-free survival in women with triple-negative breast cancer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r2K5m1
via IFTTT